07:00 , Mar 12, 2007 |  BioCentury  |  Product Development

Key to bladder relief

KeyNeurotek AG thinks that KN 203, a mu opioid receptor agonist that it recently in-licensed from pain specialist Gruenenthal GmbH, will work as a treatment for urinary incontinence without causing constipation, analgesia or dependence. It's...
08:00 , Feb 19, 2007 |  BC Week In Review  |  Company News

KeyNeurotek, Max Planck Society deal

KeyNeurotek received exclusive rights to Max Planck’s method for identifying drug candidates that have an effect on FK506 binding proteins. The company also amended its collaboration with the society’s enzymology unit to include an...